VLRX / Valeritas, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

CYGM / Cleaner Yoga Mat, Inc. 15-12B - - 15-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38038 Valeritas Holdings, Inc. (Exact name of registrant as specified in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 1, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Amendment No. 2 to Asset Purchase Agreement.

Execution Version AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 2, dated as of April 1, 2020 (this “Amendment No. 2”), to the Asset Purchase Agreement (the “Agreement”), dated as of February 9, 2020, by and among Zealand Pharma A/S, a Danish limited liability company organized and existing under the laws of Kingdom of Denmark (“Purchaser”) and one or more other persons designated

CYGM / Cleaner Yoga Mat, Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. NT 10-K - - NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-38038 CUSIP NUMBER 91914N 301 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr

CYGM / Cleaner Yoga Mat, Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

CYGM / Cleaner Yoga Mat, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

The date of this Supplement No. 2 to Prospectus Supplement is March 30, 2020.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-220799 Supplement No. 2 dated March 30, 2020 to Prospectus Supplement dated March 22, 2019 (to Prospectus dated December 15, 2017) This Supplement No. 2 to Prospectus Supplement supplements and amends the Prospectus Supplement dated March 22, 2019, or the ATM Prospectus Supplement, which updated and superseded that Prospectus Supplement dated J

Valeritas Receives Court Approval of Sale of Business to Zealand Pharma Will Result in the Retention of the Vast Majority of Valeritas Employees Enables Continued Production and Distribution of V-Go® Wearable Insulin Delivery Device

Valeritas Receives Court Approval of Sale of Business to Zealand Pharma Will Result in the Retention of the Vast Majority of Valeritas Employees Enables Continued Production and Distribution of V-Go® Wearable Insulin Delivery Device BRIDGEWATER, New Jersey, March 20, 2020 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 20, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Amendment No.1 to Asset Purchase Agreement.

Execution Version AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 1, dated as of March 17, 2020 (this “Amendment No. 1”), to the Asset Purchase Agreement (the “Agreement”), dated as of February 9, 2020, by and among Zealand Pharma A/S, a Danish limited liability company organized and existing under the laws of Kingdom of Denmark (“Purchaser”) and one or more other persons designated

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 17, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 12, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 February 25, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Asset Purchase Agreement by and among Zealand Pharma A/S as Purchaser, and Valeritas, Inc. and Valeritas Holdings, Inc., as Sellers

Execution Version ASSET PURCHASE AGREEMENT Dated as of February 9, 2020 By and Among ZEALAND PHARMA A/S as Purchaser, and VALERITAS, INC.

Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 February 10, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 February 5, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees Company and Subsidiaries Commence Voluntary Chapter 11 to Facilitate Value-Maximizing Sale Commercially Successful Business to Continue as Usual During Court-Su

Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees Company and Subsidiaries Commence Voluntary Chapter 11 to Facilitate Value-Maximizing Sale Commercially Successful Business to Continue as Usual During Court-Supervised Sale Process Commitment Obtained for Debtor-in-Possession Financing to Support Ongoing Operations BRIDGEWATER, New Jersey, February 9, 2020 - Valeritas Holdings, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 January 6, 2020 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 December 18, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

CYGMD / Valeritas Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Valeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full Year

Valeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full Year BRIDGEWATER, N.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 December 20, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Valeritas Corporate Presentation NASDAQ: VLRX December 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer t

valeritascorporatedeckde Valeritas Corporate Presentation NASDAQ: VLRX December 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 December 9, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting

Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting Presentation of data sets for both 40mg and 76mg of CBD Isolate Delivered via h-Patch™ System BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 December 9, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 18, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 15, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Valeritas Announces Third Quarter 2019 Financial Results US Revenue Grew 30% Year-Over-Year

Valeritas Announces Third Quarter 2019 Financial Results US Revenue Grew 30% Year-Over-Year BRIDGEWATER, New Jersey, November 12, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 12, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38038 Valeritas Holding

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study - Company Plans to Explore Opportunities with Industry Partners Looking to Treat Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis with Incretin Mimetic - BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 21, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

VLRX / Valeritas, Inc. 10-Q/A - Quarterly Report - 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38038 Va

VLRX / Valeritas, Inc. 10-Q/A - Quarterly Report - 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38038 V

VLRX / Valeritas, Inc. CORRESP - -

DLA Piper LLP (US) 51 John F. Kennedy Parkway Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com Emilio Ragosa, Esq. [email protected] T 973.307.3004 F 973.215.2804 October 4, 2019 Via UPS Overnight Delivery Division of Corporation Finance Office of Electronics and Machinery U.S. Securities & Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Lynn Dicker Re

TRANSACTIONS DURING PAST 60 DAYS

EX-99.A Exhibit A TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of common stock of the Issuer during the past 60 days: Reporting Person Date of Transaction Transaction Type (Purchase or Sale) Shares Price Capital Royalty Partners II L.P. 9/30/19 Purchase 1,704,890 * ** Capital Royalty Partners II (Cayman) L.P. 9/30/19 Purchase 602,493 * ** C

VLRX / Valeritas, Inc. / Capital Royalty L.p. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)* Valeritas Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 91914N 301 (CUSIP Number) Andrei Dorenbaum CR Group L.P. 1000 Main

Series B Purchase Agreement, dated as of September 30, 2019, by and among the Company, CRG and WCAS.

Execution Version SERIES B PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES B PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of September 30, 2019, by and among CAPITAL ROYALTY PARTNERS II L.

Series B Certificate of Designation.

Execution Version CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF VALERITAS HOLDINGS, INC.

Amended and Restated Series A Certificate of Designation.

Execution Version AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF VALERITAS HOLDINGS, INC.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 30, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commiss

Amendment No. 2 to Term Loan, dated as of September 30, 2019, by and among Valeritas, Inc. and CRG.

EXECUTION VERSION AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT THIS AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT (this “Amendment”), dated as of September 30, 2019, is made among VALERITAS, INC., a Delaware corporation (“Borrower”), VALERITAS HOLDINGS, INC., a Delaware corporation (“Holdings”), VALERITAS SECURITY CORPORATION, a Massachusetts corporation

Amendment No. 1 to Registration Rights Agreement, dated as of September 30, 2019, by and among the Company, CRG and WCAS.

Execution Version REGISTRATION RIGHTS AGREEMENT AMENDMENT NO.1 THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Registration Rights Agreement made and entered into effective as of February 14, 2017 by and among VALERITAS HOLDINGS, INC., a Delaware corporation (the “Company”) and CAPITAL ROYALTY PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II—PARALLEL FUND “A” L.P., PARALLEL INVESTMENT OPPORTU

Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock - Debt Exchange Expected to Save Approximately $8 Million in Cash Interest Expense - - Provides Corporate Updates

Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock - Debt Exchange Expected to Save Approximately $8 Million in Cash Interest Expense - - Provides Corporate Updates Including Expectation That Third Quarter U.S. Revenue Will Grow 30% Over Prior Year - BRIDGEWATER, New Jersey, October 2, 2019 - Valeritas Holdings, I

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 September 20, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commiss

Valeritas Corporate Presentation NASDAQ: VLRX September 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer

ex991092019 Valeritas Corporate Presentation NASDAQ: VLRX September 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 September 12, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commiss

Continuous SubQ Infusion of CBD via the h-Patch™ ©2019 Valeritas, Inc. Oral CBD Achilles’ Heel • Inconsistent Dosing as a result of: • Very poor overall bioavailability • High intra- and inter-subject pharmacokinetic variability • Large food effect •

ex991091319 Continuous SubQ Infusion of CBD via the h-Patch™ ©2019 Valeritas, Inc.

Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 September 12, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commiss

CYGMD / Valeritas Holdings, Inc. / UBS Group AG - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Valeritas Holdings Inc (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 91914N301 (CUSIP Number) August 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 September 3, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

VLRX / Valeritas, Inc. S-1/A - - S-1/A

As filed with the Securities and Exchange Commission on September 5, 2019 Registration No.

VLRX / Valeritas, Inc. CORRESP - -

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, NJ 08807 September 5, 2019 VIA EDGAR Russell Mancuso Branch Chief United States Securities and Exchange Commission Division of Corporation Finance Office of Electronics and Machinery 100 F Street, N.E. Washington, DC 20549-4561 Re: Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-232868 Ladies and Gentlema

VLRX / Valeritas, Inc. S-1/A - - S-1/A

S-1/A 1 s-1aaspire2.htm S-1/A As filed with the Securities and Exchange Commission on August 30, 2019 Registration No. 333-232868 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VALERITAS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict

VLRX / Valeritas, Inc. CORRESP - -

DLA Piper LLP (US) 51 John F. Kennedy Parkway Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com Emilio Ragosa, Esq. [email protected] T 973.307.3004 F 973.215.2804 August 30, 2019 Via UPS Overnight Delivery Division of Corporation Finance Office of Electronics and Machinery U.S. Securities & Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Heather Perciv

VLRX / Valeritas, Inc. S-1/A - - S-1/A

As filed with the Securities and Exchange Commission on August 22, 2019 Registration No.

Amended and Restated Certificate of Incorporation of the Registrant, as amended (Incorporated by reference, Exhibit 3.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-232868), filed August 22, 2019).

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VALERITAS HOLDINGS, INC. Valeritas Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”) , originally incorporated on May 9, 2014 as a Florida corporation under the name Cleaner Yoga Mat, Inc., and merged with and into Valeritas Holdings, Inc., a Delaware corporation, pursuan

VLRX / Valeritas, Inc. CORRESP - -

DLA Piper LLP (US) 51 John F. Kennedy Parkway Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com Emilio Ragosa, Esq. [email protected] T 973.307.3004 F 973.215.2804 August 22, 2019 Via UPS Overnight Delivery Division of Corporation Finance Office of Electronics and Machinery U.S. Securities & Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Heather Perciv

Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint

Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint Use of Regular Human Insulin could save U.S. patients with type 2 diabetes and healthcare systems thousands of dollars per patient annually BRIDGEWATER, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) - Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology comp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 15, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Holdings, Inc. Condensed Consolidated Balance Sheets (Dollars in thousands, except share and per share data)

Valeritas Announces Second Quarter 2019 Financial Results Year-Over-Year Volume Growth in Target Accounts Grew 36% BRIDGEWATER, N.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 8, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which was filed with the SEC on August 8, 2019;

10-Q 1 vlrx10q63019.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001

First Amendment to Lease, dated February 11, 2019, by and between BPR 293 Equity Partners, LLC and Valeritas, Inc.

FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “Amendment”) is made as of the 11th day of February 2019 (the “Effective Date”) by and between BPR 293 EQUITY PARTNERS, LLC, a Massachusetts limited liability company (“Landlord”), and VALERITAS, INC.

- Parkinson’s Disease Therapeutic Apomorphine Delivery via the h-Patch™ Offers Advantages Over Subcutaneous Injections and Bulky Belt-worn Pump Devices - - Company Plans to Explore Partnering Opportunities with Apomorphine Therapeutics Companies -

Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine - Parkinson’s Disease Therapeutic Apomorphine Delivery via the h-Patch™ Offers Advantages Over Subcutaneous Injections and Bulky Belt-worn Pump Devices - - Company Plans to Explore Partnering Opportunities with Apomorphine Therapeutics Companies - BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 5, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 30, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Press release dated July 30, 2019.

Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study - Company Plans to Explore Partnering Opportunities with CBD Therapeutics Companies - - Company to Host a Conference Call Today, July 30, 2019 at 11:00 AM ET - BRIDGEWATER, New Jersey, July 30, 2019 - Valeritas Holdings, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 26, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Power of Attorney (included in the signature page to the Registrant’s Registration Statement on Form S-1(File No. 333-232868), filed July 29, 2019)

As filed with the Securities and Exchange Commission on July 26, 2019 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 16, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 9, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 8, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device

Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device BRIDGEWATER, New Jersey, June 27, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 27, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 25, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 10, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

8-K 1 vlrx-8xkpressreleasemay292.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 29, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other juri

Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance

Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance BRIDGEWATER, New Jersey, May 29, 2019 - Valeritas Holdings, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 22, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population

Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population BRIDGEWATER, New Jersey, May 22, 2019 - Valeritas Holdings, Inc.

Valeritas Announces Reverse Stock Split

Valeritas Announces Reverse Stock Split BRIDGEWATER, New Jersey, May 17, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

8-K 1 vlrx-8kresultsofthestockho.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 16, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other juri

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 10, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas Corporate Presentation NASDAQ: VLRX May 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to pur

art1507revdvaleritasc07e Valeritas Corporate Presentation NASDAQ: VLRX May 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 9, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fil

Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance 30% Year-Over-Year Growth in Target Account Prescriptions

Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance 30% Year-Over-Year Growth in Target Account Prescriptions BRIDGEWATER, New Jersey, May 9, 2019 - Valeritas Holdings, Inc.

our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, which was filed with the SEC on May 9, 2019;

10-Q 1 vlrx10q33119.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Valeritas Expects First Quarter Revenue of $6.4 million

Valeritas Expects First Quarter Revenue of $6.4 million BRIDGEWATER, New Jersey, May 2, 2019 - Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced today it expects to report revenue of approximately $6.4 million for the first quarter ended March 31, 2019. In addition, Valeritas does not expect any significant changes

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 2, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fil

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14% BRIDGEWATER, New Jersey, April 26, 2019 --- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company an

art1561revaaacepressrele Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 26, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Amended and Restated Employee Stock Purchase Plan (included as Appendix B to the Registrant’s Definitive Proxy Statement on Form 14A, filed April 10, 2019).

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.

Press release dated April 8, 2019.

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment BRIDGEWATER, New Jersey, April 8, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 8, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 29, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-198807 46-5648907 (State or other jurisdiction of incorporation) (Commission

Preliminary Proxy

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.

THE SUPPLEMENTAL INVENTOR PRESENTATION

(two filings)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 29, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Announces V-Go® Distribution Agreement in Israel BRIDGEWATER, New Jersey, March 28, 2019 --- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, we

art1538revaexplorecommer Valeritas Announces V-Go® Distribution Agreement in Israel BRIDGEWATER, New Jersey, March 28, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 28, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

$10,303,225 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220799 PROSPECTUS SUPPLEMENT (To Prospectus dated December 15, 2017) $10,303,225 Common Stock This prospectus supplement relates to the issuance and sale of up to $10,303,225 of shares of our common stock from time to time through our sales agent, B. Riley FBR, Inc., or B. Riley FBR, the “sales agent.” These sales, if any, wil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 5, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Valeritas Corporate Presentation NASDAQ: VLRX March 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to p

exhibit991030619 Valeritas Corporate Presentation NASDAQ: VLRX March 2019 Improving health and simplifying life for people with diabetes 1 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities.

Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results Company Will Host a Conference Call and Webcast Today, March 5, at 4:30 PM ET

Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results Company Will Host a Conference Call and Webcast Today, March 5, at 4:30 PM ET BRIDGEWATER, N.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 5, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 6, 2019;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38038 Valeritas Holdings, Inc. (Exact

VLRX / Valeritas, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

VLRX / Valeritas, Inc. / Empery Asset Management, LP - VALERITAS HOLDINGS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Valeritas Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 91914N202 (CUSIP Number) December 31, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which

Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies

Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

8-K 1 a8-k011419.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 January 14, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of

VLRX / Valeritas, Inc. / UBS Group AG - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Valeritas Holdings Inc (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 91914N202 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Valeritas Announces V-Go® is Preferred on Humana Part D Formularies

Valeritas Announces V-Go® is Preferred on Humana Part D Formularies BRIDGEWATER, New Jersey, January 3, 2019 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 January 3, 2019 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 December 31, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

VLRX / Valeritas, Inc. / Empery Asset Management, LP - VALERITAS HOLDINGS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Valeritas Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 91914N202 (CUSIP Number) November 16, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which

Power of Attorney. Reference is made to page II-5 of this Registration Statement.

As filed with the Securities and Exchange Commission on December 7, 2018 Registration No.

Power of Attorney. Reference is made to page II-5 of this Registration Statement.

As filed with the Securities and Exchange Commission on December 7, 2018 Registration No.

TRANSACTIONS DURING PAST 60 DAYS

Exhibit A Exhibit A TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of common stock of the Issuer during the past 60 days: Reporting Person Date of Transaction Transaction Type (Purchase or Sale) Shares Price/Share Capital Royalty Partners II L.

VLRX / Valeritas, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

VLRX / Valeritas, Inc. / Capital Royalty L.p. - SCHEDULE 13D/A (AMENDMENT NO. 1) Activist Investment

Schedule 13D/A (Amendment No. 1) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* Valeritas Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 91914N 202 (CUSIP Number) Andrei Dorenbaum

Financial Statements and Exhibits, Other Events

8-K 1 a8-k112018.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 15, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of

Valeritas Announces Pricing of $36 Million Public Offering

Valeritas Announces Pricing of $36 Million Public Offering BRIDGEWATER, N.J., November 15, 2018 (GLOBE NEWSWIRE) - Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go®ç Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the pricing of its underwritten public offering of (i) 75 mill

Valeritas Holdings, Inc. 75,000,000 Shares of Common Stock Series A Warrants to Purchase 75,000,000 Shares of Common Stock Series B Warrants to Purchase 75,000,000 Shares of Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No.

VLRX / Valeritas, Inc. S-1MEF

As filed with the Securities and Exchange Commission on November 15, 2018 Registration No.

Power of Attorney (incorporated by reference to the registrant’s Registration Statement on Form S-1 (File No. 333-226958)).

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on November 14, 2018 Registration No.

Form of Warrant Agency Agreement (Incorporated by reference, Exhibit 4.5 to the Registrant's Registration Statement on Form S-1/A (File No. 333-226958), filed November 15, 2018)

Exhibit 4.5 VALERITAS HOLDINGS, INC. and WEST COAST STOCK TRANSFER, INC. as Warrant Agent Warrant Agency Agreement Dated as of , 2018 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2018 (“Agreement”), between Valeritas Holdings, Inc., a Delaware corporation (the “Company”), and West Coast Stock Transfer, Inc., a Delaware corporation (the “WCST” or the Warrant Agent”). W I T N E S

Form of Warrant Agency Agreement.

Exhibit 4.5 VALERITAS HOLDINGS, INC. and WEST COAST STOCK TRANSFER, INC. as Warrant Agent Warrant Agency Agreement Dated as of , 2018 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2018 (“Agreement”), between Valeritas Holdings, Inc., a Delaware corporation (the “Company”), and West Coast Stock Transfer, Inc., a Delaware corporation (the “WCST” or the Warrant Agent”). W I T N E S

Form of Series A Warrant (Incorporated by reference, Exhibit 4.3 to the Registrant's Registration Statement on Form S-1/A (File No. 333-226958), filed November 14, 2018)

Exhibit 4.3 FORM OF SERIES [A][B] WARRANT VALERITAS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Number of Shares of Common Stock: Date of Issuance: [ ], 2018 (“Issuance Date”) CUSIP: ISIN: VALERITAS HOLDINGS, INC., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are her

Form of Underwriting Agreement

Exhibit 1.1 Shares of Common Stock Series A Warrants to Purchase up to Shares of Common Stock Series B Warrants to Purchase up to Shares of Common Stock VALERITAS HOLDINGS, INC. UNDERWRITING AGREEMENT , 2018 Oppenheimer & Co. Inc., as Representative of the several Underwriters named in Schedule I hereto c/o Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Valer

VLRX / Valeritas, Inc. S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2018 Registration No.

Form of Series B Warrant (Incorporated by reference, Exhibit 4.4 to the Registrant's Registration Statement on Form S-1/A (File No. 333-226958), filed November 14, 2018)

Exhibit 4.4 FORM OF SERIES [A][B] WARRANT VALERITAS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Number of Shares of Common Stock: Date of Issuance: [ ], 2018 (“Issuance Date”) CUSIP: ISIN: VALERITAS HOLDINGS, INC., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are her

VLRX / Valeritas, Inc. CORRESP

DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, NJ 07078-2704 www.dlapiper.com Emilio Ragosa [email protected] T 973.307.3004 F 973.215.2804 Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer November 14, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Was

VLRX / Valeritas, Inc. CORRESP

November 14, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: VALERITAS HOLDINGS, INC. Registration Statement on Form S-1 (Registration No. 333-226958) Concurrence in Acceleration Request Ladies and Gentlemen: Oppenheimer & Co. Inc., as representative of the underwriters (the “Representative” and each of Oppenheimer & Co

VLRX / Valeritas, Inc. CORRESP

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, NJ 08807 November 14, 2018 VIA EDGAR Russell Mancuso Branch Chief United States Securities and Exchange Commission Division of Corporate Finance Office of Electronics and Machinery 100 F Street, N.E. Washington, D.C. 20549 Re: Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-226958 Ladies and Gentlemen: In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commiss

Valeritas Reports Record Revenue for the Third Quarter 2018 - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth -

Valeritas Reports Record Revenue for the Third Quarter 2018 - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth - BRIDGEWATER, New Jersey, November 9, 2018 - Valeritas Holdings, Inc.

Valeritas Reports Record Revenue for the Third Quarter 2018 - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth -

Valeritas Reports Record Revenue for the Third Quarter 2018 - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth - BRIDGEWATER, New Jersey, November 9, 2018 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 November 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

VLRX / Valeritas, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38038 Valeritas Holding

VLRX / Valeritas, Inc. CORRESP

October 26, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: VALERITAS HOLDINGS, INC. Registration Statement on Form S-1 (Registration No. 333-226958) Concurrence in Acceleration Request Withdrawal Ladies and Gentlemen: Oppenheimer & Co. Inc., as representative of the underwriters (the “Representative” and each of Oppenhe

VLRX / Valeritas, Inc. CORRESP

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, NJ 08807 October 26, 2018 VIA EDGAR Russell Mancuso Branch Chief United States Securities and Exchange Commission Division of Corporation Finance Office of Electronics and Machinery 100 F. Street, N.E. Washington, D.C. 20549 Re: Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-226958 Ladies and Gentlement:

VLRX / Valeritas, Inc. CORRESP

October 25, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: VALERITAS HOLDINGS, INC. Registration Statement on Form S-1 (Registration No. 333-226958) Concurrence in Acceleration Request Ladies and Gentlemen: Oppenheimer & Co. Inc., as representative of the underwriters (the “Representative” and each of Oppenheimer & Co I

VLRX / Valeritas, Inc. S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on October 23, 2018 Registration No.

VLRX / Valeritas, Inc. CORRESP

DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, NJ 07078-2704 www.dlapiper.com Emilio Ragosa [email protected] T 973.307.3004 F 973.215.2804 Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer October 24, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Wash

VLRX / Valeritas, Inc. CORRESP

BTIG, LLC 825 Third Avenue New York, New York 10022 October 23, 2018 VIA FACSIMILE AND EDGAR U.

VLRX / Valeritas, Inc. CORRESP

Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 October 23, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: VALERITAS HOLDINGS, INC. Registration Statement on Form S-1 (Registration No. 333-226958) Concurrence in Acceleration Request Ladies and Gentlemen: Oppenheimer & Co. Inc., as representative of the u

VLRX / Valeritas, Inc. CORRESP

DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, NJ 07078-2704 www.dlapiper.com Emilio Ragosa [email protected] T 973.307.3004 F 973.215.2804 Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer October 23, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Wash

VLRX / Valeritas, Inc. CORRESP

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, NJ 08807 October 23, 2018 VIA EDGAR Russell Mancuso Branch Chief United States Securities and Exchange Commission Division of Corporate Finance Office of Electronics and Machinery 100 F Street, N.E. Washington, D.C. 20549 Re:Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-226958 Ladies and Gentlemen: In a

VLRX / Valeritas, Inc. CORRESP

National Securities Corporation 200 Vesey Street New York, New York 10281 October 23, 2018 VIA FACSIMILE AND EDGAR U.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 15, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Expects to Report Record Revenue for Third Quarter 2018 Third consecutive quarter with greater than 30% year-over-year revenue growth

Valeritas Expects to Report Record Revenue for Third Quarter 2018 Third consecutive quarter with greater than 30% year-over-year revenue growth BRIDGEWATER, New Jersey, October 15, 2018 - Valeritas Holdings, Inc.

Form of Underwriting Agreement.

Exhibit 1.1 Shares VALERITAS HOLDINGS, INC. Common Stock UNDERWRITING AGREEMENT , 2018 Oppenheimer & Co. Inc., as Representative of the several Underwriters named in Schedule I hereto c/o Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Valeritas Holdings, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herei

VLRX / Valeritas, Inc. S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on October 12, 2018 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 11, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Holdings, Inc. 2018 Inducement Plan, Form of Stock Option Grant Notice and Option Agreement (Incorporated by reference, Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed October 12, 2018)

Valeritas Holdings, Inc. 2018 Inducement Plan Notice of Grant of Stock Option Notice is hereby given of the following option grant (the “Option”) to purchase shares of the Common Stock of Valeritas Holdings, Inc. (the “Corporation”): Optionee: Grant Date: Vesting Commencement Date: Exercise Price per share: $ Number of Option Shares: Expiration Date: Type of Option: Non-Statutory Stock Option Exer

Valeritas Holdings, Inc. Form of 2018 Inducement Plan (Incorporated by reference, Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed October 12, 2018)

Valeritas Holdings, Inc. 2018 Inducement Plan Adopted by the Board of Directors: [ ], 2018 ARTICLE ONE: GENERAL PROVISIONS I.PURPOSE OF THE PLAN The Plan, through the granting of Awards, is intended to (i) help the Company secure and retain the services of eligible award recipients, (ii) provide an inducement material for such persons to enter into employment with the Company or an affiliate withi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 12, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Corporate Presentation NASDAQ: VLRX October 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc. Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicit

valeritascorporatedeck Valeritas Corporate Presentation NASDAQ: VLRX October 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 10, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes

Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes BRIDGEWATER, New Jersey, October 10, 2018 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 October 2, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas’ V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes

Valeritas’ V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes BRIDGEWATER, New Jersey, October 2, 2018 - Valeritas Holdings, Inc.

VLRX / Valeritas, Inc. S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on September 25, 2018 Registration No.

VLRX / Valeritas, Inc. CORRESP

CORRESP 1 filename1.htm DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, NJ 07078-2704 www.dlapiper.com Emilio Ragosa [email protected] T 973.307.3004 F 973.215.2804 Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer September 25, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street,

VLRX / Valeritas, Inc. CORRESP

DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, NJ 07078-2704 www.dlapiper.com Emilio Ragosa [email protected] T 973.307.3004 F 973.215.2804 Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer September 7, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Was

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 23, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia

Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia BRIDGEWATER, New Jersey, August 23, 2018 - Valeritas Holdings, Inc.

VLRX / Valeritas, Inc. S-1

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 21, 2018 Registration No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc. Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicita

valeritasinvestordeck Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc. Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicita

valeritasinvestordeck891 Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

VLRX / Valeritas, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38038 Valeritas Holdings, In

Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth - Company’s Fourth Consecutive Quarter of Record Revenue and Third Consecutive Quarter with Year-Over-Year Revenue Growth Exceeding 20% -

Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth - Company’s Fourth Consecutive Quarter of Record Revenue and Third Consecutive Quarter with Year-Over-Year Revenue Growth Exceeding 20% - BRIDGEWATER, New Jersey, August 7, 2018 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 7, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 6, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia

Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia BRIDGEWATER, New Jersey, August 6, 2018 - Valeritas Holdings, Inc.

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections BRIDGEWATER, New Jersey, August 2, 2018 - Valeritas Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 August 2, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

EX-99.2

Amended and Restated 2016 Equity Incentive Plan (Incorporated by reference, Exhibit 99.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-226305), filed July 23, 2018).

Valeritas Holdings, Inc. Second Amended and Restated 2016 Incentive Compensation Plan ARTICLE ONE: GENERAL PROVISIONS I. PURPOSE OF THE PLAN This Second Amended and Restated 2016 Incentive Compensation Plan is intended to promote the interests of Valeritas Holdings, Inc., a Delaware corporation, by providing eligible persons in the Corporation’s service with the opportunity to participate in one o

Power of Attorney. Reference is made to page 3 of this Registration Statement.

As filed with the Securities and Exchange Commission on July 23, 2018 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 20, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Valeritas Holdings, Inc. 10,000,000 Shares of Common stock

Filed pursuant to Rule 424(b)(3) Registration No. 333-226018 PROSPECTUS Valeritas Holdings, Inc. 10,000,000 Shares of Common stock This prospectus relates to the sale of up to 10,000,000 shares of our common stock by Aspire Capital Fund, LLC. Aspire Capital is also referred to in this prospectus as the selling stockholder. The prices at which the selling stockholder may sell the shares will be det

VLRX / Valeritas, Inc. CORRESP

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, New Jersey 08807 July 13, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4561 Attention: Suzanne Hayes Assistant Director Re: Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-226018 Ladies and Gentleman: Pursuant to Rule 461 under t

Employment Agreement, dated January 8, 2018, by and between Valeritas, Inc. and Joseph Saldanha

EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of January 8, 2018 by and between Valeritas, Inc.

VLRX / Valeritas, Inc. S-1

As filed with the Securities and Exchange Commission on June 29, 2018 Registration No.

Form of Lock-Up and No Short Selling Agreement for 80% of shares held prior to the 2016 Merger, by and between the Registrant and certain shareholders (Incorporated by reference, Exhibit 10.4 to Registrant's Registration Statement on Form S-1 (File No. 333-226018), filed June 29, 2018).

Exhibit 10.4 FORM OF LOCK-UP AGREEMENT This LOCK-UP AGREEMENT (this “Agreement”) is made as of May 3, 2016 by the undersigned person or entity (the “Restricted Holder”) in connection with the Merger (as defined below) and the Private Placement Offering (as defined below), and is being delivered to Valeritas Holdings, Inc. (formerly Cleaner Yoga Mat, Inc.), a Delaware corporation (the “Parent”), We

Common Stock Purchase Agreement, dated June 11, 2018 between the Registrant and Aspire Capital Fund, LLC (Incorporated by reference, Exhibit 10.42 to the Registrant's Registration Statement on Form S-1 (File No. 333-226018), filed June 29, 2018).

Execution Copy COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Registration Rights Agreement, dated as of June 11, 2018, by and between the Registrant and Aspire Capital (Incorporated by reference, Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-226018), filed June 29, 2018).

Execution Copy REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Amendment to the Registrant's 2016 Equity Incentive Plan (Incorporated by reference, Exhibit 10.8.1 to Registrant's Registration Statement on Form S-1 (File No. 333-226018), filed June 29, 2018).

AMENDMENT TO THE VALERITAS HOLDINGS, INC. 2016 INCENTIVE COMPENSATION PLAN This Amendment (this “Amendment”) to the Valeritas Holdings, Inc. 2016 Incentive Compensation Plan (the “Plan”), is effective (the “Effective Date”) as of the effectiveness of that certain registration statement (SEC No. 333-215897) of Valeritas Holdings, Inc. (the “Company”). WHEREAS, the Company maintains the Plan; WHEREA

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 25, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes

Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes - Data Presented at Annual ADA Meeting Reports Patients with Type 2 Diabetes who Switched to V-Go® had Significant Improvement in Blood Glucose and Used Less Insulin - BRIDGEWATER, N.

VLRX / Valeritas, Inc. DEF 14A

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.

Common Stock Purchase Agreement, dated June 11, 2018 between Valeritas Holdings, Inc. and Aspire Capital Fund, LLC

Execution Copy COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2018 Date of Report (Date of earliest event reported): Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissio

Registration Rights Agreement, dated June 11, 2018, between Valeritas Holdings, Inc. and Aspire Capital Fund, LLC

Execution Copy REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2018 Date of Report (Date of earliest event reported): Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

Registration Rights Agreement, dated June 11, 2018, between Valeritas Holdings, Inc. and Aspire Capital Fund, LLC

Execution Copy REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Common Stock Purchase Agreement, dated June 11, 2018 between Valeritas Holdings, Inc. and Aspire Capital Fund, LLC

Execution Copy REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2018, by and between VALERITAS HOLDINGS, INC.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 31, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas Corporate Presentation NASDAQ: VLRX May 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc. Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitatio

valeritasinvestordb34 Valeritas Corporate Presentation NASDAQ: VLRX May 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 23, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes BRIDGEWATER, N.

Valeritas Announces V-Go® Distribution Agreement in Austria and Germany

Valeritas Announces V-Go® Distribution Agreement in Austria and Germany BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

8-K 1 a8-k52118.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 21, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incor

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 18, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes

Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 14, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes BRIDGEWATER, New Jersey, May 23, 2018 - Valeritas Holdings, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 11, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission Fi

Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6%

Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a8-k5918.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorpo

VLRX / Valeritas, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-198807 Valeritas Holdings,

VLRX / Valeritas, Inc. 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38038 Valeritas Ho

Valeritas Announces Pricing of $24 Million Public Offering of Common Stock

Valeritas Announces Pricing of $24 Million Public Offering of Common Stock BRIDGEWATER, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 24, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission

13,700,000 Shares Valeritas Holdings, Inc. Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to 424(b)(4) Registration No.

VLRX / Valeritas, Inc. S-1MEF

As filed with the Securities and Exchange Commission on April 23, 2018 Registration No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 17, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-198807 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Announces V-Go® Distribution Agreement in Australia and New Zealand

Valeritas Announces V-Go® Distribution Agreement in Australia and New Zealand BRIDGEWATER, New Jersey, April 12, 2018 - Valeritas Holdings, Inc.

Valeritas Teams with Glooko as its Preferred Data Management Partner for V-Go® SIM™

Valeritas Teams with Glooko as its Preferred Data Management Partner for V-Go® SIM™ BRIDGEWATER, New Jersey, April 20, 2018 - Valeritas Holdings, Inc.

VLRX / Valeritas, Inc. CORRESP

Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 April 19, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: VALERITAS HOLDINGS, INC. Registration Statement on Form S-1 (Registration No. 333-223903) Concurrence in Acceleration Request Ladies and Gentlemen: Oppenheimer & Co. Inc. (“Oppenheimer”), as represent

VLRX / Valeritas, Inc. CORRESP

Valeritas Holdings, Inc. 750 Route 202 South, Suite 600 Bridgewater, NJ 08807 April 19, 2018 VIA EDGAR Russell Mancuso Branch Chief United States Securities and Exchange Commission Division of Corporate Finance Office of Electronics and Machinery 100 F Street, N.E. Washington, D.C. 20549 Re: Valeritas Holdings, Inc. Registration Statement on Form S-1 File No. 333-223903 Ladies and Gentlemen: In ac

Form of Underwriting Agreement.

Shares VALERITAS HOLDINGS, INC. Common Stock UNDERWRITING AGREEMENT , 2018 Oppenheimer & Co. Inc., as Representative of the several Underwriters named in Schedule I hereto c/o Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Valeritas Holdings, Inc., a Delaware corporation (the "Company") proposes, subject to the terms and conditions contained herein, to sell t

VLRX / Valeritas, Inc. S-1/A

As filed with the Securities and Exchange Commission on April 13, 2018 Registration No.

Other Events

8-K 1 a8-k41318.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 13, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of inc

VLRX / Valeritas, Inc. S-1/A

As filed with the Securities and Exchange Commission on April 9, 2018 Registration No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 April 9, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-198807 46-5648907 (State or other jurisdiction of incorporation) (Commission

Employment Agreement, dated January 8, 2018, by and between Valeritas, Inc. and Joseph Saldanha (Incorporated by reference, Exhibit 10.41 to Registrant's Registration Statement on Form S-1 (File No. 333-223903), filed March 26, 2018).

EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of January 8, 2018 by and between Valeritas, Inc.

Power of Attorney (contained on signature page hereto).

As filed with the Securities and Exchange Commission on March 23, 2018 Registration No.

Power of Attorney. Reference is made to page II-5 of this Registration Statement.

As filed with the Securities and Exchange Commission on March 20, 2018 Registration No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 7, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 March 12, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-198807 46-5648907 (State or other jurisdiction of incorporation) (Commission

Valeritas Corporate Presentation NASDAQ: VLRX March 2018 ©2018 Valeritas, Inc.. Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.. 2 NASDAQ: VLRX John Timberlake, CEO Improving health and simplifying life for people

art1236revavaleritasinve Valeritas Corporate Presentation NASDAQ: VLRX March 2018 ©2018 Valeritas, Inc.

VLRX / Valeritas, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38038 Valeritas Holdings, Inc. (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 February 26, 2018 Date of report (Date of earliest event reported) Valeritas Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38038 46-5648907 (State or other jurisdiction of incorporation) (Commissi

Valeritas Reports Fourth Quarter and Full Year 2017 Financial Results Company Will Host a Conference Call and Webcast Today, February 26, at 4:30 PM ET

Exhibit Valeritas Reports Fourth Quarter and Full Year 2017 Financial Results Company Will Host a Conference Call and Webcast Today, February 26, at 4:30 PM ET BRIDGEWATER, N.